NEW YORK (GenomeWeb News) – Protein biomarker company Peakadilly today said it has raised €8.5 million ($10.9 million) in the second and final round of its series A financing.
Peakadilly said it will use the cash to increase the capacity of its protein biomarker-discovery operation, which is based on its MASStermind technology.
It will also enable it to “accelerate development of its own diagnostic and pharmacodiagnostic products,” the firm said.
The investment brings to €14.5 million the total amount of venture capital Peakadilly has raised. The Ghent, Belgium-based company raised €6 million in March in its first series A round.
Investors in the second round were GIMV, Life Science Partners, KBC Private Equity, and Baekeland Fonds II.